Atlas Trials

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Clinical trial NCT02159495 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02159495
Sponsor
City of Hope Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Adult Acute Myeloid Leukemia in RemissionAcute Biphenotypic LeukemiaEarly Relapse of Acute Myeloid LeukemiaLate Relapse of Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmAcute Myeloid LeukemiaAdult Acute Lymphoblastic LeukemiaInterleukin-3 Receptor Subunit Alpha PositiveMinimal Residual DiseaseRefractory Acute Myeloid Leukemia
Start date
2015-12-15
Primary completion
2026-08-06
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.